RxDoctor Payments Data

Alexis Harman, MD

Family Medicine · Brooklyn, NYNPI 1962889899

Payments from drug & device makers

$3,137in general payments, 2019–2025

Across 57 payments — averaging $55.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$787
  • Novo Nordisk$285
  • Lilly USA, LLC$228
  • AstraZeneca$218
  • Boehringer Ingelheim$200
  • Gilead$171
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,137100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,137 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$6,193
Medicare patients
34
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide106$142,371
JardianceEmpagliflozin87$79,079
FarxigaDapagliflozin Propanediol58$52,568
JanumetSitagliptin Phos/Metformin Hcl54$47,905
OzempicSemaglutide35$35,326
EliquisApixaban39$32,457
JanuviaSitagliptin Phosphate33$23,846
TradjentaLinagliptin21$19,416
MounjaroTirzepatide15$16,983
Diclofenac Sodium ErDiclofenac Sodium177$13,145
Tresiba Flextouch U-100Insulin Degludec21$10,937
EntrestoSacubitril/Valsartan11$9,608
XareltoRivaroxaban16$9,479
Victoza 3-PakLiraglutide12$9,155
SynjardyEmpagliflozin/Metformin Hcl12$6,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$228$159,355121 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy$200$105,357120 claims
AstraZenecaFarxiga$218$52,56858 claims
Novo NordiskOzempic$285$35,32635 claims
PfizerEliquis$159$32,45739 claims
AbbVieSynthroid$22$1,68517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.

Other family medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →